Peptide education
Glutathione
GSH · Reduced L-glutathione · gamma-glutamyl-cysteinyl-glycine
Glutathione is a three-amino-acid molecule, glutamate, cysteine, and glycine, that your cells make for themselves and use as their main internal antioxidant. It handles peroxides, recycles itself, and helps conjugate reactive compounds so they can be cleared. Because that chemistry touches so much biology, the market sells it for everything: detox, immunity, skin lightening, hangovers, Parkinson's, anti-aging. The human evidence supports a much smaller claim: some repeated oral and liposomal regimens can raise glutathione markers in blood and tissue. Whether raising those markers improves anything a person can feel is a different, mostly unanswered question.
The one finding glutathione research keeps reproducing is that certain oral and liposomal products can raise glutathione levels. The detox, skin-IV, and anti-aging claims are built on top of that finding, not underneath it.
Overview
Quick answer
Glutathione is included as a peptide-adjacent support compound. The public conversation mixes oral supplements, liposomal products, topical cosmetics, inhaled or intranasal studies, compounded sterile injectables, clinic IV add-ons, and an ophthalmic irrigating solution component. Those product and route contexts need to be judged separately.
What is it?
Glutathione, or GSH, is a tripeptide your own cells synthesize, and the most abundant intracellular antioxidant you have. In the marketplace it shows up as a supplement, a liposomal liquid, a cream, an IV add-on, and a compounded injection.
What do people use it for?
Detox, immune support, skin brightening, liver markers, hangovers, and anti-aging, plus specialist research in Parkinson's disease, cystic fibrosis, chemotherapy neuropathy, and diabetes. The evidence is strongest for moving glutathione markers and weakest exactly where the marketing is loudest.
What study and market-use patterns are reported?
Trials used oral 250 to 500 mg per day, 500 mg twice daily, or liposomal 500 to 1000 mg per day, running 4 weeks to 6 months; Parkinson's research used 1400 mg IV three times a week. Clinic IV pushes of 200 to 600 mg come from menus, not trials.
Why do route and product type matter?
Because the evidence changes with the route. An oral study that moved markers says nothing about a skin cream, and nothing any oral study found can make an IV skin-lightening drip safe or effective. That corner of the market carries FDA-documented endotoxin and adverse-event history.
Reported practice
Commonly reported protocol
Clinic IV push programs. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Repeated oral and liposomal studies report increases in body stores or blood markers. Those marker changes are not the same as broad detox, anti-aging, disease-treatment, or performance benefits.
Clinic, med-spa, marketplace, and advertising sources commonly discuss detox, skin, immune, rapid-absorption, and wellness claims. They show how the product is marketed, not whether those effects happen.
Oral and topical cosmetic studies have short-term signals, while IV skin lightening has weak efficacy support and prominent safety warnings.
FDA highlighted adverse events and endotoxin concerns when a dietary ingredient glutathione material was used to compound sterile injectables.
Platinum-chemotherapy adjunct work and Parkinson's trials are medical research contexts. Broad detox, cosmetic, and wellness claims are different claims.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Glutathione raises glutathione levels. | A single 3 g oral dose did not meaningfully raise circulating glutathione in older pharmacokinetic work. Later repeated-dose oral and liposomal studies reported increases in body stores, blood markers, or immune markers, depending on the formulation and study. | Glutathione is synthesized inside cells and participates in redox cycling, so the biological target is real. Clinical relevance depends on whether the studied product raises glutathione in the relevant tissue and whether that change improves symptoms or health outcomes. | Supplement and liposomal-product marketing often treats absorption as finished science. The human data support a narrower statement: some repeated regimens can move markers. | Partly supported for markers. Broad clinical benefit claims would need stronger outcome data than the marker-focused evidence here. |
| Glutathione is an established detox therapy. | Human supplementation studies have not shown broad detox outcomes. The better-supported human findings are marker changes, selected small pilots, and route-specific disease studies. | Glutathione participates in conjugation chemistry and peroxide handling, which explains the detox language. A product still needs outcome evidence to show faster toxin clearance or a measurable wellness benefit. | Clinic and marketplace pages commonly use detox, immune, energy, and hangover-style language, especially around IV drips and liposomal products. | Glutathione chemistry helps explain detox marketing, but the cited human evidence does not prove it works as a broad detox treatment. |
| Glutathione lightens skin. | Small oral studies used 500 mg/day for 4 weeks or 250 mg/day for 12 weeks and reported modest cosmetic signals. A topical matched-face study reported local cosmetic effects. IV skin-lightening evidence is much weaker and comes with stronger safety concerns. | The proposed dermatology mechanism involves oxidative biology and melanin pathways, including tyrosinase-related discussion in reviews. | Cosmetic and med-spa markets often promote injectable or IV glutathione for skin brightening, especially in gray-market and international skin-whitening contexts. | Narrow oral or topical cosmetic signals can be described, but IV skin whitening remains a high-caution claim with limited support and real harm reports. |
| IV glutathione works better because oral glutathione is poorly absorbed. | Older oral pharmacokinetic work supports skepticism about a single large oral dose. Later repeated oral and liposomal studies complicate that simple claim because some oral regimens did move markers. | IV exposure can raise plasma glutathione quickly, but the rise is short lived. Tissue delivery, intracellular repletion, and clinical benefit still need evidence for each use. | Med-spa and clinic pages often present IV delivery as rapid and superior. That claim usually skips the difference between transient plasma exposure and lasting clinical benefit. | Too simple. IV changes exposure, but it also adds sterile-product risk and leaves the marketed outcome unproven. |
| Glutathione treats Parkinson's disease. | The IV Parkinson's pilot used 1400 mg three times weekly for 4 weeks and was small. Intranasal randomized work and route-mixed reviews do not make a routine Parkinson's treatment case. | Oxidative-stress biology makes Parkinson's research worth studying, but that rationale has not produced a decisive route-specific clinical answer. | Neurologic and wellness discussions may treat glutathione as a brain or mitochondrial support tool. Those discussions are less reliable than the named clinical trials. | Investigational at most. It is not an established Parkinson's therapy. |
| Glutathione helps chemotherapy-related neuropathy. | Older cisplatin-adjunct work reported a neuroprotection signal, while a later paclitaxel/carboplatin phase 3 context was negative. The research question is chemotherapy-regimen specific. | Platinum chemotherapy and redox biology make this a plausible specialist setting, but antioxidant effects may also be complicated in oncology. | Wellness marketing often uses the word antioxidant from oncology-adjunct contexts without the oncology supervision or regimen specificity. | Mention as a narrow oncology-adjunct research area, not as a general neuropathy, detox, or wellness rationale. |
| Liposomal or nano glutathione is automatically superior. | A liposomal pilot reported marker changes at 500 or 1000 mg/day for 4 weeks. That does not mean every liposomal or nano-branded product has the same exposure, quality, or clinical outcome. | Delivery systems can change absorption, but product-specific formulation and testing matter. | Marketplace and advertising claims often emphasize rapid absorption, immune support, detox, or efficacy language. Some absorption and efficacy claims have drawn advertising-substantiation scrutiny. | Product-specific evidence is needed. Liposomal or nano branding is not class-wide clinical evidence. |
Bottom line
Main takeaway
Glutathione is real and important inside your cells, which is not the same as saying a supplement or drip does anything useful. The solid evidence ends at raising measurable levels.
Judge each format on its own data: oral and liposomal products have marker evidence, skin creams have small cosmetic studies, and IV glutathione has weak efficacy support plus a genuine safety file.
The backbone is Witschi 1992, Allen 2011, Richie 2015, Sinha 2018, the small skin trials, the Parkinson's and cystic fibrosis studies, and the FDA compounding alert. Clinic menus are market documentation, not evidence.
Identity
What it is
Glutathione is gamma-glutamyl-cysteinyl-glycine, three amino acids joined into the cell's dominant redox buffer. It neutralizes peroxides through glutathione peroxidase, couples to reactive compounds through glutathione-S-transferases, and gets recycled back to its active form.
That chemistry is why it gets marketed so hard. Detox, immunity, skin pigment, liver enzymes, neurodegeneration, cancer therapy: glutathione touches all of it at the biochemical level, and marketers read "touches" as "treats."
The pharmacology has a catch the marketing skips. A single large oral dose barely moves blood levels, and IV dosing spikes plasma only briefly; the interesting modern finding is that repeated daily oral or liposomal regimens can raise body stores over weeks. What nobody has shown is that raising those stores produces the detox, skin, or anti-aging outcomes being sold.
How people talk about it online
Online, glutathione is sold as the body's master antioxidant in a bottle: detox, glowing skin, immunity, hangover recovery, anti-aging. The phrase "poorly absorbed" then does the upsell, pushing liposomal liquids and IV drips as the premium fix.
The skin-lightening end of the market is the dangerous one. IV glutathione for skin brightening has weak efficacy evidence, documented liver, kidney, and severe skin reactions, and explicit regulatory warnings in multiple countries.
The IV boom also has a paper trail: FDA reported adverse events and endotoxin contamination when dietary-ingredient glutathione was used to compound sterile injectables. That history applies to every med-spa push and gray-market vial, whatever the menu promises.
Use context
Routes, doses, and cycle patterns
Glutathione needs route, formulation, and study setting named plainly. Human studies give concrete oral, liposomal, topical, inhaled, intranasal, and IV research regimens. Clinics and marketplaces add detox, wellness, cosmetic, and rapid-absorption claims, often without usable amounts, control groups, or durable outcome data.
Human studies and product labels
Single-dose oral pharmacokinetic study
- Purpose
- Testing whether one large oral dose raised circulating glutathione
- Context
- Human pharmacokinetic study
- Route
- Oral
- Amount
- 3 g single dose
- Frequency
- One-time dose
- Duration
- Acute pharmacokinetic sampling
This older study is why many discussions say unmodified oral glutathione is poorly available. It leaves another question: whether repeated oral or liposomal regimens can move tissue or blood markers.
Oral oxidative-stress biomarker RCT
- Purpose
- Systemic oxidative-stress biomarker testing
- Context
- Randomized, double-blind, placebo-controlled trial
- Route
- Oral
- Amount
- 500 mg twice daily
- Frequency
- Twice daily
- Duration
- 4 weeks
The trial found no significant changes in systemic oxidative-stress biomarkers. It is included because it tempers broad antioxidant claims.
Six-month oral body-store study
- Purpose
- Glutathione body-store and immune-marker effects
- Context
- Randomized controlled trial
- Route
- Oral
- Amount
- The cited summary does not give a usable dose amount
- Frequency
- Daily
- Duration
- 6 months
The study reported increased glutathione stores and immune-marker discussion. The result is marker-focused, not a broad health outcome.
Liposomal oral pilot
- Purpose
- Body-store and immune-marker changes
- Context
- Pilot clinical study
- Route
- Oral liposomal
- Amount
- 500 or 1000 mg/day
- Frequency
- Daily
- Duration
- 4 weeks
This is the strongest formulation-specific liposomal signal cited here. It supports a marker claim for the studied product, not every liposomal or nano-labeled product.
NAFLD pilot
- Purpose
- Liver enzyme and metabolic marker changes
- Context
- Open-label multicenter pilot
- Route
- Oral
- Amount
- 300 mg/day
- Frequency
- Daily
- Duration
- 4 months
ALT and triglyceride improvements were reported in a single-arm pilot. Without placebo control, this remains early liver-marker evidence.
Parkinson's IV pilot
- Purpose
- Parkinson's symptom and tolerability research
- Context
- Randomized, placebo-controlled, double-blind pilot
- Route
- Intravenous
- Amount
- 1400 mg
- Frequency
- Three times weekly
- Duration
- 4 weeks
The study was small and did not establish IV glutathione as a Parkinson's treatment.
Intranasal Parkinson's study
- Purpose
- Parkinson's safety and symptom research by non-IV route
- Context
- Randomized, double-blind phase I/IIa study
- Route
- Intranasal
- Amount
- Reviewed summary did not report the study-specific amount
- Frequency
- Study-specific schedule
- Duration
- 3 months
No substantial improvements were described after 3 months. This stays separate from IV glutathione claims.
Oral skin-lightening study
- Purpose
- Cosmetic skin-color outcomes
- Context
- Randomized placebo-controlled trial
- Route
- Oral
- Amount
- 500 mg/day in two divided doses
- Frequency
- Daily
- Duration
- 4 weeks
A small skin-lightening signal was reported. The short duration and cosmetic endpoint limit how far the claim can go.
Oral reduced or oxidized glutathione skin study
- Purpose
- Pigmentation and cosmetic skin-quality measures
- Context
- Randomized placebo-controlled trial
- Route
- Oral
- Amount
- 250 mg/day
- Frequency
- Daily
- Duration
- 12 weeks
This supports oral cosmetic discussion, not IV whitening claims.
Topical oxidized glutathione matched-face study
- Purpose
- Cosmetic skin measures
- Context
- Double-blind, placebo-controlled matched-face trial
- Route
- Topical
- Amount
- 0.5 g applied to one side of the face
- Frequency
- Twice daily
- Duration
- 10 weeks
This topical cosmetic study does not support systemic supplement or injectable claims.
Inhaled cystic fibrosis study
- Purpose
- Lung-function and pulmonary outcomes in cystic fibrosis
- Context
- Randomized controlled trial
- Route
- Inhaled
- Amount
- 646 mg in 4 mL in one RCT
- Frequency
- Study-specific schedule
- Duration
- Multimonth RCT context
The mixed, specialized results do not support broad respiratory or immune claims for general use.
Type 2 diabetes oxidative-stress trial
- Purpose
- Redox and metabolic-marker changes
- Context
- Randomized clinical trial
- Route
- Oral
- Amount
- 500 mg/day
- Frequency
- Daily
- Duration
- 6 months
The study reported redox-marker and glycemic-effect signals, with stronger interpretation in older participants. It needs replication before it becomes a treatment claim.
Real-world discussion
Clinic IV push programs
- Purpose
- Antioxidant, recovery, and skin-tone discussion
- Context
- IV clinics and med-spas
- Route
- Intravenous push, often added to other drips
- Amount
- Clinic menus commonly describe 200 to 600 mg per session, sometimes higher
- Frequency
- One to three sessions per week in clinic programs
- Duration
- Sold as multi-session packages or ongoing
The skin-lightening marketing attached to high-dose IV glutathione has drawn specific regulatory warnings in several countries, and the evidence for the marketed outcomes is weak. Not verified as a regimen; context only.
Oral liposomal supplements
- Purpose
- Antioxidant support
- Context
- Retail supplement market
- Route
- Oral liposomal liquids or capsules
- Amount
- Commonly marketed at 250 to 500 mg per day
- Frequency
- Once daily
- Duration
- Ongoing supplement use
Standard oral glutathione is poorly absorbed, which is why liposomal formats dominate the premium end of the market.
What varies
- Goal matters: biomarker repletion, skin brightening, liver markers, Parkinson's symptoms, cystic fibrosis inhalation, diabetes redox markers, oncology-adjunct use, and med-spa wellness are different claims.
- Route matters: oral, liposomal oral, topical, inhaled, intranasal, IV, compounded injectable, and ophthalmic irrigating-solution contexts carry different risks and evidence.
- Amount matters: study regimens range from 250 mg/day oral to 1400 mg IV three times weekly, and clinic or vendor material often does not publish a consistent amount.
- Duration matters: the human studies range from acute pharmacokinetics to 4 weeks, 10 to 12 weeks, 4 months, 6 months, and longer pulmonary contexts.
- Product type matters: a supplement, a liposomal product, a compounded sterile injectable, and an FDA-labeled ophthalmic irrigating solution are not interchangeable.
- Quality matters: identity, assay, sterility, endotoxin, ingredient grade, storage, shipping, and representative lot testing are different checks.
Human data
Human evidence
The human record is a collection of small, route-specific studies rather than a coherent case. A 1992 pharmacokinetic study found a 3 g oral dose did not meaningfully raise circulating glutathione, and a 2011 randomized trial found no change in systemic oxidative-stress biomarkers at 500 mg twice daily. Against that, six months of daily oral dosing and a 4-week liposomal pilot did raise body stores and some immune markers. Skin studies are small and cosmetic; NAFLD and diabetes signals are preliminary; Parkinson's, cystic fibrosis, and chemotherapy-adjunct work are narrow medical contexts with mixed results. Nothing in this record supports the broad detox, hangover, anti-aging, or IV skin-lightening claims, and the IV end of the market carries FDA-documented sterility and endotoxin problems.
Evidence maturity
Human evidence supports moving glutathione markers with certain oral and liposomal regimens; the broad detox, anti-aging, and IV claims rest on much weaker ground.
An endogenous tripeptide central to redox balance, peroxide handling, and conjugation chemistry.
A 1992 human study found a single large oral dose did not meaningfully raise circulating glutathione.
Repeated oral and liposomal randomized studies reported increased body stores and blood or immune markers, not clinical outcomes.
Small trials in skin, NAFLD, diabetes, Parkinson's, cystic fibrosis, and chemotherapy-adjunct settings produced mixed or preliminary signals.
Detox, anti-aging, and IV skin-lightening claims lack outcome support, and FDA flagged endotoxin problems with compounded injectables.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Witschi 1992 oral availability study | Healthy volunteers | Human pharmacokinetic study | Oral glutathione | A single 3 g oral dose did not meaningfully raise circulating glutathione to a clinically useful extent. | Single-dose pharmacokinetics leave repeated oral or liposomal use open for tissue stores and clinically meaningful markers. | Moderate for single-dose oral availability; weak for clinical outcomes |
| Allen 2011 oral glutathione RCT | Healthy volunteers | Randomized, double-blind, placebo-controlled trial | Oral supplement | 500 mg twice daily for 4 weeks did not significantly change systemic oxidative-stress biomarkers. | Small study, biomarker endpoints, and short duration. | Moderate for null biomarker finding; weak for broad health outcomes |
| Richie 2015 oral supplementation RCT | Healthy adults | Randomized controlled trial | Oral supplement | Six months of daily oral glutathione increased glutathione body stores in the reported trial summary. | Marker-focused outcome; no broad disease or wellness benefit shown. | Moderate for marker repletion |
| Sinha 2018 liposomal glutathione pilot | Healthy adults | Pilot clinical study | Oral liposomal product | 500 or 1000 mg/day for 4 weeks elevated body stores and some immune markers. | Small, short, and formulation-specific. | Weak to moderate for marker repletion |
| Honda 2017 NAFLD pilot | Adults with NAFLD | Open-label multicenter pilot | Oral supplement | 300 mg/day for 4 months was associated with ALT and triglyceride improvements. | Single-arm design means lifestyle changes, regression to the mean, and other factors cannot be ruled out. | Weak |
| Oral and topical skin studies | Healthy adults or healthy women in cosmetic studies | Small randomized or matched-face cosmetic trials | Oral or topical cosmetic use | Oral 500 mg/day for 4 weeks, oral 250 mg/day for 12 weeks, and topical matched-face use reported modest short-term cosmetic skin signals. | Small studies, short duration, cosmetic endpoints, and poor transfer to IV skin-whitening claims. | Weak to moderate for narrow cosmetic endpoints |
| IV glutathione in Parkinson's disease | People with Parkinson's disease | Randomized placebo-controlled pilot | Intravenous research protocol | 1400 mg three times weekly for 4 weeks was studied, but the trial was too small to establish treatment efficacy. | Small sample, short duration, and route-specific design. | Weak |
| Intranasal glutathione in Parkinson's disease | People with Parkinson's disease | Randomized, double-blind phase I/IIa trial | Intranasal investigational route | No substantial improvements were reported after 3 months. | Early-phase and route-specific; it does not answer IV or oral claims. | Weak |
| Cystic fibrosis inhalation studies | People with cystic fibrosis | Randomized controlled trials | Inhaled investigational use | The pulmonary outcome signals were mixed, including transient or limited effects. | Specialized disease context and inhaled route limit how far this can be applied to broad immune or respiratory supplement claims. | Weak to moderate for specialized research; weak for general claims |
| Platinum-chemotherapy adjunct studies | Patients receiving specific chemotherapy regimens | Randomized chemotherapy-adjunct studies | Specialist medical protocol | Cisplatin-adjunct work showed a neuroprotection signal, while a paclitaxel/carboplatin phase 3 context was negative. | Regimen-specific oncology context under specialist care; not a general wellness or neuropathy claim. | Mixed specialist evidence |
Cautions
Safety and unknowns
- Oral and topical studies are generally short and too small to establish long-term safety for chronic supplement or cosmetic use.
- IV and compounded injectable use adds sterility, endotoxin, ingredient grade, compounding, infection, and adverse-reaction risks that oral and topical studies do not answer.
- FDA reported adverse events and endotoxin concerns tied to dietary-ingredient glutathione used for sterile compounding.
- Cosmetic IV use has reported concerns including liver and kidney problems, hypersensitivity, severe skin reactions, and regulatory warnings in the reviewed sources.
- Oncology contexts are complicated because glutathione biology can interact with chemotherapy sensitivity and tumor-cell survival pathways.
- Pregnancy, breastfeeding, asthma or reactive airway disease, liver or kidney disease, active cancer treatment, and chemotherapy contexts require case-specific medical judgment, not wellness extrapolation.
Product quality
A vial label is only a starting point
For injectables, a purity number is only one check. Sterility, endotoxin, ingredient grade, concentration, storage, and compounding context decide whether the product is suitable for that route.
A supplement COA or marketplace purity claim is not enough to show suitability for sterile injection.
Liposomal or nano branding is product-specific unless the exact formulation has human evidence.
An ophthalmic irrigating solution component does not create an FDA-approved systemic glutathione wellness product.
Identity and assay
Identity testing helps confirm the ingredient, but route, sterility, and clinical-effect claims still need their own evidence.
Sterility and endotoxin
Injectable products require sterile-quality controls. FDA's glutathione alert shows why endotoxin and ingredient-grade mismatch are not theoretical issues.
Formulation and route
Oral, liposomal, topical, inhaled, intranasal, ophthalmic, and IV products have different exposure and safety questions.
Storage and stability
Reconstituted and compounded materials may degrade or be mishandled, and marketplace storage claims rarely document proper handling.
Product category
Supplements, GRAS food uses, compounded drugs, and FDA-labeled products are different legal categories.
Mechanism
How it is proposed to work
Glutathione works inside cells as a redox buffer. In plain terms, it helps manage reactive chemistry, supports peroxide handling, and participates in conjugation reactions that help cells process electrophilic compounds.
Reduced glutathione cycles with oxidized glutathione through glutathione reductase and NADPH-dependent chemistry.
Glutathione peroxidases use glutathione to reduce hydrogen peroxide and lipid hydroperoxides, linking the molecule to oxidative-stress biology.
Glutathione-S-transferase systems use glutathione in conjugation reactions, which explains why detox language appears in marketing even when human detox outcomes remain unconfirmed.
In skin biology, reviews discuss antimelanogenic and antioxidant mechanisms, but small cosmetic signals do not settle IV safety or long-term pigmentation claims.
In cancer biology, glutathione can be context-dependent because high intracellular glutathione may also support resistance to some therapies.
Glutathione is the tripeptide Glu-Cys-Gly and the cell's dominant intracellular antioxidant. The pharmacokinetic problem is upstream: oral glutathione is largely hydrolyzed before absorption, and a single large dose barely moves blood levels.
FAQ
Common questions
Is glutathione a peptide?
Glutathione is an endogenous tripeptide and a common clinic-market term. It fits better as peptide-adjacent than as a peptide-protocol topic.
Is injectable glutathione recommended?
Injectable glutathione raises route-specific safety and quality questions. The sources here do not define one standard product, route, dose, schedule, or regimen.
Can cosmetic skin-lightening claims be treated as established?
No. The reviewed evidence and regulatory warnings point to a warning-forward interpretation rather than a favorable cosmetic claim.
Details
Technical details
Sources
References
- 1.
FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act 2026.
Accessed 2026-06-09.
FDA explains the 503A bulk-substance framework, interim categories, and conditions; this is not FDA approval of a finished glutathione product.
- 2.
FDA. June 8, 2022 Pharmacy Compounding Advisory Committee materials for glutathione 2022.
Accessed 2026-06-09.
FDA PCAC meeting materials for glutathione; useful for compounding-policy context, not for consumer-use instructions.
- 3.
FDA. FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables 2019.
Accessed 2026-06-09.
FDA compounding alert describing adverse-event reports, endotoxin concerns, ingredient-grade concerns, and sterile-injectable quality boundaries.
- 4.
Accessed 2026-06-09.
Department of Justice enforcement source involving unapproved injectable skin-whitening drug claims.
- 5.
Other. Injectable gluta for whitening not supported by DOH 2024.
Accessed 2026-06-09.
Philippine News Agency report quoting Philippines Department of Health context on injectable glutathione, cisplatin-adjunct approval context, and skin-lightening claims.
- 6.
Other. Efficacy of intravenous glutathione vs. placebo for skin tone lightening 2016.
doi:10.66344/jpad.26.3.2016.18 Accessed 2026-06-09.
Small placebo-controlled IV glutathione skin-tone study source; is used for weak efficacy context and serious adverse-event concerns.
- 7.
PubMed. Intravenous glutathione for skin lightening: Inadequate safety data 2016.
doi:10.7196/SAMJ.2016.v106i8.10878 PMID:27499402 Accessed 2026-06-09.
Dermatology safety review source for IV glutathione skin-lightening claims.
- 8.
PubMed. The clinical effect of glutathione on skin color and other related skin conditions: A systematic review 2019.
doi:10.1111/jocd.12910 PMID:30895708 Accessed 2026-06-09.
Systematic review source for separating oral, topical, and IV skin-color evidence.
- 9.
Other. Glutathione for skin lightening: a regnant myth or evidence-based verity? 2018.
Accessed 2026-06-09.
Open-access dermatology review discussing limited evidence and safety/regulatory concerns for parenteral glutathione skin-lightening use.
- 10.
doi:10.1200/JCO.1995.13.1.26 Accessed 2026-06-09.
Oncology-adjunct source lead for reduced glutathione in a cisplatin-related neurotoxicity context.
- 11.
PMID:24619793 Accessed 2026-06-09.
Phase 3 trial source showing oncology-adjunct findings do not generalize uniformly across chemotherapy regimens.
- 12.
PubMed. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease 2009.
doi:10.1002/mds.22401 PMID:19230029 Accessed 2026-06-09.
Small randomized IV Parkinson's pilot source; useful for route-specific evidence boundaries.
- 13.
PubMed. Potential use of glutathione as a treatment for Parkinson's disease 2021.
doi:10.3892/etm.2020.9557 PMID:33376507 Accessed 2026-06-09.
Parkinson's review source; route-mixed evidence is not clean IV glutathione evidence.
- 14.
PubMed. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease 2015.
doi:10.1002/mds.26351 PMID:26230671 Accessed 2026-06-09.
Route-mismatch source showing that some Parkinson's glutathione evidence is intranasal rather than injectable.
- 15.
PubMed. High-dose intravenous glutathione in man: pharmacokinetics and effects on cyst(e)ine in plasma and urine 1991.
doi:10.1111/j.1365-2362.1991.tb01366.x PMID:1907548 Accessed 2026-06-09.
Human IV pharmacokinetic source for transient plasma exposure context.
- 16.
Accessed 2026-06-09.
Recent case-report source for severe systemic reaction after unregulated cosmetic IV glutathione-containing infusion.
- 17.
NCI and PubChem. NCI Drug Dictionary and PubChem glutathione entries.
Identity and classification.
- 18.
Witschi 1992 oral PK. Witschi et al. 1992 systemic availability of oral glutathione.
Single-dose oral bioavailability skepticism.
- 19.
Allen 2011 oral RCT. Allen et al. 2011 oral glutathione and oxidative-stress biomarkers randomized trial.
Oral biomarker trial context.
- 20.
Sinha 2018 liposomal. Sinha et al. 2018 oral liposomal glutathione pilot study.
Liposomal formulation marker evidence.
- 21.
Honda 2017 NAFLD. Honda et al. 2017 open-label NAFLD pilot.
Liver-marker pilot context.
- 22.
Griese 2013 CF. Griese et al. 2013 inhaled glutathione in cystic fibrosis.
Inhaled cystic-fibrosis outcome context.
- 23.
Calabrese 2015 CF. Calabrese et al. 2015 inhaled glutathione versus placebo in cystic fibrosis.
Longer inhaled cystic-fibrosis trial context.
- 24.
Arjinpathana 2012 skin. Arjinpathana et al. 2012 oral glutathione skin-lightening study.
Cosmetic skin signal.
- 25.
Weschawalit 2017 skin. Weschawalit et al. 2017 antiaging and antimelanogenic glutathione study.
Cosmetic skin signal.
- 26.
Watanabe 2014 topical. Watanabe et al. 2014 topical oxidized glutathione study.
Topical cosmetic signal.
- 27.
FDA supplement framework. FDA dietary-supplement consumer information and Part 111 framework.
Supplements are not preapproved like drugs.
- 28.
FDA compounded-drug risks. FDA compounded-drug risk pages.
Compounded drugs are not FDA-approved.
- 29.
Med-spa and marketplace claims. Med-spa, clinic, and marketplace glutathione listings.
Detox, skin, immune, and rapid-absorption claims.
- 30.
NAD advertising scrutiny. BBB and NAD-related reporting on nano glutathione claims.
Advertising-substantiation context.
- 31.
Skin-lightening warnings. Philippine FDA advisory and government reporting on unsafe skin-lightening use.
Cosmetic injectable warning context.
- 32.
Oncology caution reviews. Cancer reviews on glutathione and chemoresistance.
Context-dependent oncology caution.
- 33.
Kalamkar 2022 diabetes. Kalamkar et al. 2022 long-term glutathione supplementation in type 2 diabetes.
Exploratory metabolic marker use case.